Opdivo nivolumab: Additional Phase I/II data

Data from a cohort of 127 patients with advanced small cell lung cancer (SCLC) in the open-label, international Phase I/II CheckMate -032 showed that IV Opdivo plus Yervoy ipilimumab led to

Read the full 315 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE